Luis Palacios is Chief Executive Officer of Elystone Capital SA, a boutique wealth management firm that he founded in 2002. Previously, Mr. Palacios was a private banker at Bank Morgan Stanley AG, establishing the firm’s wealth management practice in Geneva. Prior to this, he was a private banker at Hentsch & Cie. Mr. Palacios received his bachelor’s degree in industrial engineering from the Universidad Catolica Argentina, Buenos Aires and his MBA degree from INSEAD, Fontainebleau, France.
Angelos M. Stergiou, MD brings more than 15 years of experience in the global pharmaceutical industry, leading companies and people from scientific research through regulatory approval to develop medicines that address compelling medical needs. Prior to joining SELLAS, Dr. Stergiou held positions of increasing responsibility in the United States and Europe in pharma and biotechnology companies including PAION AG, Accentia Biopharmaceuticals, BioVest International, Anavex Life Sciences as well as Clinical Research Organizations. Dr. Stergiou has held specific roles ranging from Medical Director, Head of Clinical Research, Vice President and President, Product Development, with responsibility for medical affairs, clinical research and development, pharmacovigilance and clinical operations, among other functions. Dr. Stergiou is a Fellow of the Royal Society of Medicine (UK) and holds a Doctor of Medicine degree and is a graduate of Kentucky Wesleyan (USA).
Dr. Miltos K. Sugiultzoglu, MD, is an accomplished corporate development professional with a broad understanding of all aspects of clinical development and medical affairs. Dr. Sugiultzoglu has worked in the pharmaceutical industry as consultant for private companies across various disciplines. He holds a degree in Biomedical Engineering as well as a Medical Degree from Boston University. Dr. Sugiultzoglu completed his Residency in Neurosurgery at Cornell Medical Center – Memorial Sloan Kettering Cancer Center in New York, and has done extensive research in Boston and Rockefeller University.
Gregory Raskin, MD is Vice President, Technology Development at Memorial Sloan Kettering Cancer Center (MSK), where he leads technology transfer, commercialization, and business development at the world’s oldest and largest private cancer center. Prior to joining MSKCC in 2012, Dr. Raskin was a Vice President at Alliance Bernstein LP, where he led healthcare and life sciences investing for the firm’s $200 million venture capital fund. Dr. Raskin’s previous experience includes serving as a biotech analyst at Baker Brothers Investments and as a management consultant at McKinsey & Company, where he worked mainly with pharmaceutical and biotech companies.
Dr. Raskin received both his bachelor’s degree in molecular biophysics and biochemistry and his medical degree from Yale University. Dr. Raskin also was a resident physician in the internal medicine department of New York University Medical Center.
Alexander Schwartz is Lawyer at Schwärzler Attorneys at Law in Zug, Switzerland, with expertise in civil and contract law, particularly corporate and commercial law, asset management, and investment advice. Prior to this position, he was Lawyer and Managing Director of AFP Advokatur Fischer & Partner, also in Zug. Previously, Mr. Schwartz served as Law Clerk at the Public Prosecutor’s Office of the Canton of Zug. He is a member of the SAV Swiss Bar Association and a Member of the Board of Foundation of several listed companies. Mr. Schwartz studied jurisprudence at the University of Zurich and was admitted as Civil Law Notary in the Canton of Zug.